

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-046002	Application No. 09/846,512
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rachel Meyers et al.	
		Filing Date May 1, 2001	Group Art Unit 1642

## U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
my	AB	WO 98/41656	09/24/98	WIPO				
	AC	WO 00/52044	09/08/00	WIPO				
	AD	WO 00/53756	09/14/00	WIPO				
	AE	WO 00/55350	09/21/00	WIPO				
	AF	WO 00/68247	11/16/00	WIPO				
	AG	WO 00/78960	12/28/00	WIPO				
	AH	WO 01/22920	04/05/01	WIPO				
	AI	WO 01/57194	08/09/01	WIPO				
	AJ	WO 01/68848	09/20/01	WIPO				
	AK	WO 01/74897	10/11/01	WIPO				
	AL	WO 01/96388	12/20/01	WIPO				
	AM	WO 02/00860	01/03/02	WIPO				

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
my	AN	Geneseq Accession No. AAZ233949; Record dated 7-DEC-1999
	AO	Geneseq Accession No. AAY41694; Record dated 7-DEC-1999
	AP	EMBL Accession No. AI469095; Record dated 17-MAR-1999
	AQ	EMBL Accession No. AA922301; Record dated 24-APR-1998
	AR	EMBL Accession No. AX340919; Abstract
	AS	EMBL Accession No. AX341376; Abstract
	AT	EMBL Accession No. AB038157; Record dated 08-JAN-2001
	AU	Underwood et al., "TADG12, a novel serine protease overexpressed in ovarian carcinoma", Proc. Am. Assoc. for Cancer Res. Annual 41:130 (2000)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.